DeutschNewstral
Article
jdsupra.com on 2016-06-10 04:55
FDA Announces Advisory Committee Meeting on Sandoz’s Etanercept Biosimilar
Related news
- BREAKING NEWS: FDA Approves Sandoz’s Erelzi, biosimilar to Enbrel (etanercept)jdsupra.com
- FDA Advisory Committee Recommends Approval of Pfizer’s EPOGEN®/PROCRIT® Biosimilarjdsupra.com
- FDA Approves Sandoz’s Biosimilar of Enbrel®jdsupra.com
- DOC Announces Renewable Energy Advisory Committee Meetingjdsupra.com
- FDA Advisory Committee to Hold Public Meetings on Amgen’s Proposed Bevacizumab Biosimilar and Mylan’s Proposed Trastuzumab Biosimilarjdsupra.com
- Investor Advisory Committee Meetingjdsupra.com
- SEC Advisory Committee Meetingjdsupra.com
- FDA to Hold Public Meeting on Biosimilar User Feesjdsupra.com
- SEC’s Advisory Committee Meetingjdsupra.com
- FDA Announces Biosimilar User Fee Rates for FY 2017jdsupra.com
- FDA Approves Sandoz’s Biosimilar Pegfilgrastimjdsupra.com
- Lupin Announces Positive Results For Etanercept Biosimilarjdsupra.com
- Discontinuation of Etanercept Biosimilar in Japanjdsupra.com
- SEC Announces New Investor Advisory Committee Membersjdsupra.com
- Roche's Subcutaneous Rituximab Gets Unanimous Recommendation from FDA Advisory Committeejdsupra.com
- Biosimilar Development Updates: Infliximab, Ranibizumab, Etanercept, Filgrastim & Trastuzumabjdsupra.com
- FDA Approves Another Interchangeable Biosimilarjdsupra.com
- FDA Approves Sandoz Filgrastim Biosimilarjdsupra.com
- Huon Announces Prolia Biosimilarjdsupra.com
- Biomass Technical Advisory Committee Announces Public Meetingjdsupra.com